Research programme: anti-RSV monoclonal antibodies - Medarex/MedImmune

Drug Profile

Research programme: anti-RSV monoclonal antibodies - Medarex/MedImmune

Alternative Names: Anti-RSV monoclonal antibodies research programme - Medarex/MedImmune

Latest Information Update: 21 Oct 2008

Price : $50

At a glance

  • Originator Medarex; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 31 Dec 2005 No development reported - Preclinical for Respiratory syncytial virus infections in USA (unspecified route)
  • 29 Sep 2004 This programme is still in active development
  • 27 Jul 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top